- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02811653
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease (TAMA)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Daniela ANDRIUTA, PhD
- Phone Number: +33 3 22 66 82 40
- Email: andriuta.daniela@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80054
- Recruiting
- CHU Amiens
-
Contact:
- Daniela ANDRIUTA, PhD
- Phone Number: +33 3 22 66 82 40
- Email: andriuta.daniela@chu-amiens.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients
- Age between 40 and 85
- French mother tongue
- Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
- MCI, according to Albert et al.'s criteria (Albert et al., 2011)
- Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
- Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
- Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
- Social security coverage
Healthy controls
- Healthy age and gender matched volunteers will be recruited into the study from the general population.
Exclusion Criteria:
- Reading or writing difficulties related to a learning disorder or illiteracy.
A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
- NYHA stage IV dyspnoea.
- respiratory impairment requiring oxygen therapy.
- liver impairment.
- kidney failure, progressing neoplastic disease, or past or present alcohol abuse.
Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
- stroke.
- meningitis or encephalitis.
- severe head injury.
- sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
- epilepsy (requiring ongoing treatment),
- psychiatric disorders (other than treated depression).
- treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
- Impossibility to perform a neuropsychological evaluation or brain MRI.
- Withdrawal from the study at any time, if desired.
- Pregnancy
Contra-indication to MRI:
- nerve stimulators
- cochlear implants
- ferromagnetic foreign bodies close to nervous structures in the eye or brain
- cerebral shunts
- dental appliances
- Legal guardianship or incarceration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alzheimer disease
Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
|
|
Active Comparator: control
Healthy age- and gender-matched volunteers will be recruited into the study from the general population. Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
median SRT (simple reaction time) to a stimulus (in milliseconds)
Time Frame: Day 0
|
Day 0
|
Collaborators and Investigators
Investigators
- Principal Investigator: Daniela ANDRIUTA, PhD, CHU Amiens
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2015_843_0003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on neuropsychological evaluation
-
University Hospital, MontpellierUniversité MontpellierUnknown
-
Assistance Publique Hopitaux De MarseilleCompletedHirschsprung's Disease (HD)France
-
Assistance Publique Hopitaux De MarseilleUnknownAdolescents Surviving Childhood Leukemia LEAFrance
-
IRCCS Eugenio MedeaCompletedIntellectual Disability | Autism Spectrum Disorder | Attention Deficit Hyperactivity DisorderItaly
-
University Hospital, CaenRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Motoric Cognitive Risk SyndromeFrance
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; Rutgers UniversityCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Lund University HospitalCompleted